Cardiff Oncology Inc - ESG Rating & Company Profile powered by AI
If you are employed by Cardiff Oncology Inc and you wish to licence your ESG rating, please get in touch. This analysis of Cardiff Oncology Inc was assembled by All Street Sevva using proprietary artificial intelligence. Scroll down to the bottom of this webpage for potential risks for Cardiff Oncology Inc based on industry, geography and marketcap.
Cardiff Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Cardiff Oncology Inc | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cardiff Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cardiff Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Cardiff Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cardiff Oncology Inc offer flexible work?
Sign up for free to unlockDoes Cardiff Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cardiff Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cardiff Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Cardiff Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cardiff Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cardiff Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cardiff Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cardiff Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cardiff Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cardiff Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Cardiff Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Cardiff Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cardiff Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cardiff Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.